ArticlePathobiology : journal of immunopathology, molecular and cellular biology2023
GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.
Article in Pathobiology : journal of immunopathology, molecular and cellular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Diagnostic and Prognostic Roles of GATA3 Immunohistochemistry in Urothelial Carcinoma.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Immunohistochemical Evaluation of GATA3 Expression in Patch-Stage Mycosis Fungoides (MF) Compared With Benign Inflammatory Dermatoses (BID).Journal of cutaneous pathology · 2026Article
- Aberrant GATA3 reactivity in a clear cell renal cell carcinoma with clear cell papillary renal cell tumor-like features: a case report.Virchows Archiv : an international journal of pathology · 2026Article
- Interplay of ELF5, GATA-3 and FLI-1 regulate malignant transformation of keratinocytes.Scientific reports · 2026Article
- Clinical, diagnostic and prognostic relevance of GATA3 in malignant pleural mesothelioma: a retrospective cohort study.BMC cancer · 2026Article
- Clinicopathology of adenocarcinoma originating from the anal gland with immunohistochemical expressions of GATA3 and TTF-1: a case report and literature review.Frontiers in oncology · 2026Article
- Multidimensional roles and clinical significance of GATA3 in breast cancer.Frontiers in cell and developmental biology · 2026Review
- Low GATA3 predicts worse survival in penile cancer.Scientific reports · 2025Article
- Article
- Application of the Mass Spectrometry-High-Throughput Technique Over the Immunohistochemical Analysis for Human Brain Tumor Diagnosis and Prognosis: Insights Into Biomarkers' Identification for the Case Study of Grade IV Astrocytomas and Meningiomas.Biomedical chromatography : BMC · 2025Article
- Discovery of epigenetically silenced tumour suppressor genes in aggressive breast cancer through a computational approach.NAR cancer · 2025Article
- Case Report: Endoscopic submucosal dissection revealed isolated gastric metastasis from primary bladder urothelial carcinoma: clinicopathological analysis and literature review.Frontiers in medicine · 2025Article
- Comparative evaluation of PECS II versus RISS block for postoperative analgesia in breast cancer surgery: a randomized controlled trial.American journal of translational research · 2025Article
- Review
- PAX8 expression in cancerous and non-neoplastic tissue: a tissue microarray study on more than 17,000 tumors from 149 different tumor entities.Virchows Archiv : an international journal of pathology · 2024Article
- Frequency of Androgen Receptor Positivity in Tumors: A Study Evaluating More Than 18,000 Tumors.Biomedicines · 2024Article
- Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder.International urology and nephrology · 2024Article
- Prevalence and Pattern of GATA3 Immunohistochemical Expression in Female Genital Tract Adenocarcinomas.Iranian journal of pathology · 2024Article
- GATA3 Positively Correlates with BCL2 Expression in Indolent and Aggressive Histological Types of Cutaneous Basal Cell Carcinoma.Turk patoloji dergisi · 2024Article
- Automated Prognosis Marker Assessment in Breast Cancers Using BLEACH&STAIN Multiplexed Immunohistochemistry.Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGATA3 is a transcription factor involved in epithelial cell differentiation. GATA3 immunostaining is used as a diagnostic marker for breast and urothelial cancer but can also occur in other neoplasms.
methodsTo evaluate GATA3 in normal and tumor tissues, a tissue microarray containing 16,557 samples from 131 different tumor types and subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry.
resultsGATA3 positivity was found in 69 different tumor types including 23 types (18%) with at least one strongly positive tumor. Highest positivity rates occurred in noninvasive papillary urothelial carcinoma (92-99%), lobular carcinoma (98%), carcinoma of no special type of the breast (92%), basal cell carcinoma of the skin (97%), invasive urothelial carcinoma (73%), T-cell lymphoma (23%), adenocarcinoma of the salivary gland (16%), squamous cell carcinoma of the skin (16%), and colorectal neuroendocrine carcinoma (12%). In breast cancer, low GATA3 staining was linked to high pT stage (p = 0.03), high BRE grade (p < 0.0001), HER2 overexpression (p = 0.0085), estrogen and progesterone receptor negativity (p < 0.0001 each), and reduced survival (p = 0.03).
conclusionOur data demonstrate that GATA3 positivity can occur in various tumor entities. Low levels of GATA3 reflect cancer progression and poor patient prognosis in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.